Linc

Linc ROIC

The Return on Invested Capital (ROIC) of Linc (LINC.ST) as of Oct 23, 2026 is -9.02 %. In the previous year, Return on Invested Capital (ROIC) was 26.94 % — a change of -133.47% (lower).

ROIC

-9.02 %

YoY

-133.47%

Last updated:

Return on Invested Capital (ROIC) of Linc is 2025 -9.02 % . Return on Invested Capital (ROIC) of Linc was 2024 26.94 % . It decreases by -133.47% lower compared to the previous year.

The Linc ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
29.66 SEK
Jan 1, 2019
35.89 SEK
Jan 1, 2020
33.40 SEK
Jan 1, 2021
-0.83 SEK
Jan 1, 2022
-24.86 SEK
Jan 1, 2023
17.53 SEK
Jan 1, 2024
26.94 SEK
Jan 1, 2025
-9.02 SEK
The Linc ROIC history
YEARROICYoY
-9.02 %-133.47%
26.94 %+53.70%
17.53 %-170.52%
-24.86 %+2,907.43%
-0.83 %-102.47%
33.40 %-6.94%
35.89 %+21.00%
29.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linc Stock analysis

What does Linc do? Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies. Linc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linc stock

Return on Invested Capital (ROIC) of Linc is -9.02 % in 2025.

Return on Invested Capital (ROIC) of Linc changed from 26.94 % to -9.02 %, representing a -133.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Linc since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Linc with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Linc

All Key Metrics — Linc